SAMSUNG-SEMICONDUCTOR
23.12.2021 10:02:09 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today announced that it has developed the PM1743 SSD for enterprise servers, integrating the PCIe (Peripheral Component Interconnect Express) 5.0 interface with Samsung's advanced sixth-generation V-NAND.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005139/en/
"For over a decade, Samsung has been delivering SATA, SAS and PCIe-based SSDs that have been recognized for outstanding performance and reliability by leading enterprise server customers including corporations, governments and financial institutions," said Yong Ho Song, Executive Vice President and Head of the Memory Controller Development Team at Samsung Electronics. "The introduction of our PCIe 5.0 SSD, along with PCIe 6.0-based product developments that are underway, will further solidify our technological leadership in the enterprise server market."
"Intel has been working with Samsung to test Samsung's newest PCIe NVMe SSD, the PM1743. Together, we have jointly resolved complicated technical issues encountered with PCIe 5.0 during this initial evaluation period. The performance potential of Gen5 is truly impressive. In the near future, we strongly believe that PCIe Gen5 systems with high-speed NVMe SSDs will have the ability to transform applications such as AI/ML and high-performance databases," said Jim Pappas, Director, Technology Initiatives, Intel Corporation. "Looking ahead, we are confident that Intel and Samsung's continued commitment in industry leadership will provide these and other benefits to our mutual customers."
PCIe 5.0 offers a bandwidth of 32 gigatransfers per second (GT/s), doubling that of PCIe 4.0. Leveraging a proprietary controller designed to support the latest PCIe standard, the PM1743 will deliver outstanding read and write speeds to accommodate the rapidly increasing performance requirements of data centers.
Samsung’s PM1743 will feature a sequential read speed of up to 13,000 megabytes per second (MB/s) and a random read speed of 2,500K input/output operations per second (IOPS), offering 1.9x and 1.7x faster speeds over the previous PCIe 4.0-based products. Moreover, write speeds have been elevated significantly, with a sequential write speed of 6,600 MB/s and a random write speed of 250K IOPS, also delivering 1.7x and 1.9x faster speeds, respectively. These remarkable data transfer rates will allow enterprise server manufacturers deploying the PM1743 to enjoy a much higher level of performance.
In addition, the new SSD can provide improved power efficiency of up to 608 MB/s per watt, which represents about a 30% boost over the previous generation. This is expected to lower server and data center operating costs significantly, while also helping to reduce their carbon footprint.
Available in a wide variety of capacities from 1.92 terabytes (TB) to 15.36TB, the PM1743 will be offered in the conventional 2.5-inch form factor, as well as in a 3-inch EDSFF (E3.S) — an increasingly popular SSD form factor designed specifically for next-generation enterprise servers and data centers. Customers deploying 7.5mm EDSFF SSDs will be able to double the storage density in their systems, compared to when the 15mm 2.5-inch form factor is used. Coupled with excellent signal integrity and thermal efficiency, the EDSFF is ideal for most PCIe 5.0 enterprise solutions.
Furthermore, the PM1743 is expected to be the industry's first PCIe 5.0 SSD with dual-port support, guaranteeing server operational stability and high availability when a connection to one port fails.
Recently, the importance of data security has been growing stronger in the enterprise server market. To ensure that these needs are addressed, Samsung's PM1743 will implement advanced security features that were traditionally only available at the server level. By embedding a security processor and Root of Trust (RoT), the SSD will protect against security threats and data forgery to provide data confidentiality and integrity, while also enabling Secure Boot in server systems through attestation.
Samsung is now delivering samples of the PM1743 to global chipset and server manufacturers for joint system development. The company plans to begin mass producing the PM1743 in the first quarter of 2022, as it continues to foster a highly robust ecosystem for the new PCIe 5.0 standard.
The PM1743 has been designated a CES 2022 Innovation Awards Honoree in the category of Computer Hardware & Components.
###
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005139/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom